Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 10/2012

01-10-2012 | Original Article

Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study

Authors: C. Yavas, U. Dogan, G. Yavas, M. Araz, O. Yavas Ata

Published in: Supportive Care in Cancer | Issue 10/2012

Login to get access

Abstract

Objectives

Palonosetron is a novel 5-hydroxytryptamine3 (5 HT3) receptor antagonist, which has been shown to be superior to first generation 5 HT3 receptor antagonists regarding the prevention of acute, delayed and overall chemotherapy-induced nausea and vomiting. First generation 5 HT3 receptor antagonists may induce electrocardiographic changes of heart rate and repolarization. The acute cardiac effect of palonosteron is unknown. The purpose of this study is to determine acute effects of palonosetron on electrocardiographic (ECG) parameters in cancer patients.

Materials and methods

The study had a prospective design. Seventy-six cancer patients with normal cardiac function who received palonosetron for prevention of chemotherapy-induced nausea and vomiting were enrolled. Standard 12-lead ECG recordings were performed at baseline and 30 min after palonosetron administration. P wave durations and corrected QT intervals were measured; P wave dispersion (Pd) and QTc dispersion were calculated.

Results

Median heart rate did not differ among 76 patients enrolled before and after palonosetron administration (p: 0.6). Systolic and diastolic blood pressures were not significantly different before and after palonosteron (p values 0.9 and 0.3, respectively). Although median QT min value was higher after palonosetron administration than before palonosetron administration, the difference was not statistically significant (p: 0.6).

Conclusion

Palonosetron seems to have no acute arrhythmogenic potential.
Literature
1.
Aapro M, Bourke JP (2003) Rapid intravenous administration of granisetron prior to chemotherapy is not arythmogenic: results of a pilot study. Eur J Cancer 39:927–931PubMedCrossRef
2.
O'Brien BJ, Rusthoven J, Rocchi a et al (1993) Impact of chemotherapy-induced nausea and vomiting on patients' functional status and on costs: survey of five Canadian centers. Can Med Assoc J 149:296–302
3.
Navari RM (2003) Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting-two new agents. J Support Oncol 1:89–103PubMed
4.
De Leon A (2006) Palonosetron (Aloxi): a second-generation 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting. Bayl Univ Med Cent Proc 19:413–416
5.
Doherty KM (1999) Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs 3:113–119PubMed
6.
Jantunen IT, Kataja VV, Muhonen TT, Parviainen T (1996) Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother Pharmacol 37:502–504PubMedCrossRef
7.
Yavas O, Yazici M, Eren O, Boruban C, Artac M, Genc M (2008) The acute effect of tropisetron on ECG parameters in cancer patients. Support Care Cancer 16:1011–1015PubMedCrossRef
8.
Buyukavci M, Olgun Hi Ceviz N (2005) The effects of ondansetron ang granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol 28:201–204PubMedCrossRef
9.
Navari RM, Koeller JM (2003) Electrocariographic and cardiovascular effects of the 5-hydroxitryptamine 3 receptor antagonists. Ann Pharmocother 37:1276–1286CrossRef
10.
Watanabe H, Hasegawa A, Shinozaki T et al (1995) Possible cardiac side effects of granisteron an entiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol 35:278–282PubMedCrossRef
11.
Kasinath NS, Malak O, Tetzlaff J (2003) Atrial fibriallation after ondansetron for the prevention and treatment of postoperative nausea and vomiting a case report. Can J Anaesth 50:229–231PubMedCrossRef
12.
Audhuy B, Cappelaere P, Martin M et al (1996) A double-blind, randomized comparison of the antiemetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 32A(5):807–813PubMed
13.
14.
Boike SC, Ilson B, Zariffa N et al (1997) Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health Syst Pharm 54(10):1172–1176PubMed
15.
Hunt TL, Cramer M, Shah A et al (1995) A double-blind placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. J Clin Pharmocol 35(7):705–712
16.
Hesketh P, Navari R, Grote T et al (1996) Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol 14(8):2242–2249PubMed
17.
Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473–2482PubMedCrossRef
18.
Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570–1577PubMedCrossRef
19.
Morganroth J (2007) Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther 81(1):108–113PubMedCrossRef
20.
Morganroth J (2001) Focus on issues in measuring and interpreting changes in the QTc interval duration. Eur Heart J 3:105–111CrossRef
21.
Morganroth J (2007) Evaluation of the effect on cardiac repolarization (QTc interval) of oncologic drugs. Ernst Schering Res Found Workshop 59:171–184PubMedCrossRef
22.
Kris MG, Grunberg SM, Gralla RJ et al (1994) Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 12:1045–1049PubMed
23.
Lifsey DS, Gralla RJ, Clark RA, Kline RC (1993) Electrocardiographic changes with serotonin antagonist antiemetics:rate of occurrence and clinical relevance. Proc Am Soc Clin Oncol 12:463, abst 1611
24.
25.
Dilaveris PE, Gialafos EJ, Sideris SK, Theopistou AM, Andrikopoulos GK, Kyriakidis M, Gialafos JE et al (1998) Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation. Am Heart J 135:733–738PubMedCrossRef
26.
Dilaveris PE, Gialafos EJ, Andrikopoulos GK, Richter DJ, Papanikolaou V, Poralis K, Gialafos JE (2000) Clinical and electrocardiographic predictors of recurrent atrial fibrillation. Pacing Clin Electrophysiol 23:352–358PubMedCrossRef
27.
Bitzen A, Sternickel K, Lewalter T, Schwab JO, Yang A, Schrickel JW, Linhart M et al (2007) Automatic p wave analysis over 24 hours in patients with paroxysmal or persistent atrial fibrillation. Ann Noninvasive Electrocardiol 12:306–315PubMedCrossRef
28.
Bazzet HR (1920) An analysis of the time relations of electrocardiographs. Heart 7:353–370
29.
Benedict CR, Arbogast R, Martin L, Patton L, Morrill B, Hahne W (1996) Single-blind study of the effects of intravenous dalasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 28:53–59PubMedCrossRef
30.
Gray GW, McLellan TM, Ducharme MB (1996) Granisetron shows no pro-arrhythmic effect in normal subjects during or after exercise in a hot environment. Aviat Space Environ Med 67(8):759–761PubMed
31.
Lofters WS, Pater JL, Zee B et al (1997) Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 15(8):2966–2973PubMed
32.
Kuryshev YA, Brown AM, Wang L, Benedict CR, Rampe D (2000) Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther 295(2):614–620PubMed
Metadata
Title
Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study
Authors
C. Yavas
U. Dogan
G. Yavas
M. Araz
O. Yavas Ata
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 10/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-011-1348-9

Other articles of this Issue 10/2012

Supportive Care in Cancer 10/2012 Go to the issue

Original Article

Validation of the Chinese version of Multidimensional Fatigue Inventory-20 in Chinese patients with cancer

Original Article

The use of hyperbaric oxygen for treating delayed radiation injuries in gynecologic malignancies: a review of literature and report of radiation injury incidence

Original Article

Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients

Original Article

Unmet spiritual care needs impact emotional and spiritual well-being in advanced cancer patients

Original Article

Health-related quality of life in high-grade glioma patients: a prospective single-center study

Original Article

Preferred place of care and place of death of the general public and cancer patients in Japan
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits